Active Ingredient(s):Tepotinib Hydrochloride FDA Approved: * February 3, 2021 Pharm Company: *EMD SERONO INC Category:Cancer
Tepotinib, sold under the brand name Tepmetko, is a medication used for the treatment of adults with non-small cell lung cancer (NSCLC).
Tepotinib first received marketing approval in Japan, in March 2020, as a "line-agnostic" drug, meaning it is approved both for treatment-naive patients and for those in whom previous attempts at treatment have failed. U.S. approval followed in February 2021. It is the second therapy...
* May have multiple approval dates, manufacturers, or labelers.